Investing.com - H.C. Wainwright重申对Compass Pathways（纳斯达克：CMPS）的买入评级，目标价维持在$70，理由是其COMP360疗法在监管推进和商业化准备方面取得积极进展。该股过去一年累计涨幅达161% ...

Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways said it ...

心理健康医疗公司Compass Pathways Plc（CMPS）股价触及52周高点$11.65，创下重要里程碑。该股目前交易价格为$11.68，市值达15.7亿美元。过去一年间，Compass Pathways股价累计涨幅高达150%，充分反映出投资者对其创新心理健康疗法的信心持续增强。此番股价攀升至52周高位 ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact ...

Recent attention on COMPASS Pathways (CMPS) centers on its first quarter 2026 earnings and a series of key regulatory steps for COMP360 in treatment resistant depression, including a rolling FDA New ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Compass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has ...